Capricorn Fund Managers Ltd Buys Shares of 1,291,773 Adaptive Biotechnologies Corporation $ADPT

Capricorn Fund Managers Ltd purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,291,773 shares of the company’s stock, valued at approximately $17,930,000. Adaptive Biotechnologies comprises about 2.8% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 8th biggest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. California State Teachers Retirement System grew its position in shares of Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after acquiring an additional 933 shares during the period. Captrust Financial Advisors grew its stake in Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies during the fourth quarter worth about $28,000. Institutional investors own 99.17% of the company’s stock.

Insider Buying and Selling

In related news, insider Harlan S. Robins sold 6,160 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $18.01, for a total transaction of $110,941.60. Following the sale, the insider directly owned 1,405,898 shares in the company, valued at approximately $25,320,222.98. This trade represents a 0.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $19.00, for a total value of $95,000.00. Following the sale, the insider owned 411,775 shares in the company, valued at $7,823,725. The trade was a 1.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 698,316 shares of company stock valued at $11,655,488 over the last 90 days. 5.70% of the stock is currently owned by company insiders.

Adaptive Biotechnologies Trading Up 0.2%

Shares of NASDAQ ADPT opened at $21.45 on Wednesday. The firm has a market capitalization of $3.43 billion, a P/E ratio of -65.00 and a beta of 2.15. The firm’s 50-day moving average price is $15.66 and its 200-day moving average price is $15.74. Adaptive Biotechnologies Corporation has a 1-year low of $9.96 and a 1-year high of $21.64.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same period last year, the business earned ($0.20) EPS. Adaptive Biotechnologies’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. TD Cowen upped their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.